According to a recent LinkedIn post from Touchlight, the company plans to participate in the ASGCT 2026 conference in Boston from May 11–15. The post highlights that Touchlight will engage with attendees at booth 1334 to discuss its cell‑free DNA technologies, including mbDNA and Custom Circles.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Touchlight is positioning its platform as an alternative to traditional plasmid DNA, emphasizing potential advantages in speed and overcoming manufacturing constraints. For investors, visible presence at a major gene and cell therapy conference may indicate continued business development efforts, potential partnering activity, and ongoing demand for DNA manufacturing solutions in advanced therapies.